|
|
Volumn 1 Suppl 1, Issue , 2000, Pages
|
|
Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIRUBICIN;
PLASMINOGEN ACTIVATOR INHIBITOR 1;
TUMOR MARKER;
UROKINASE;
ADJUVANT CHEMOTHERAPY;
BLOOD;
BREAST TUMOR;
CANCER STAGING;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FEMALE;
HUMAN;
PATHOLOGY;
PATIENT SELECTION;
PROGNOSIS;
REVIEW;
TUMOR RECURRENCE;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
EPIRUBICIN;
FEMALE;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
PATIENT SELECTION;
PLASMINOGEN ACTIVATOR INHIBITOR 1;
PROGNOSIS;
TUMOR MARKERS, BIOLOGICAL;
URINARY PLASMINOGEN ACTIVATOR;
MLCS;
MLOWN;
|
|
EID: 0002105258
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2000.s.011 Document Type: Review |
|
Times cited : (3)
|
|
References (23)
|
